This site is intended only for healthcare professionals resident in Egypt
Sequelae & mortality
Like other vaccine-preventable diseases, meningococcal disease caused by Neisseria meningitidis is associated with high fatality.2
In 20% of survivors The impact of meningococcal disease can last a lifetime due to devastating long-term sequelae2.
Meningococcal disease is a severe infection that progresses rapidly.3
*Data are from a literature review for high-income countries, 2001–2016.3
Meningococcal disease can be difficult to diagnose and cases are potentially underreported.2
Infants are at an increased risk of meningococcal disease.2
Infants aged less than 1 year are highly vulnerable to meningococcal disease with the highest rate of disease incidence, followed by those aged 1–4 years.2
Incidence is highest in young children.
Adapted from ECDC Annual Epidemiological Report: Invasive meningococcal disease. 2017.
Sources: Country reports from Austria, Belgium, Bulgaria, Cyprus, the Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, the Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Sweden, and the United Kingdom.
IMD incidence was highest in infants and young children, with a notification rate of 8.2 confirmed cases per 100 000 population in children under one year of age.2
Adapted from Presa JV, et al. Int J Infect Dis. 2019; Villena R, et al. Vaccine. 2019; European Centre for Disease Control and Prevention (ECDC). Invasive meningococcal disease. 2019; Public Health Agency of Canada. The use of bivalent factor H binding protein meningococcal serogroup B (Men B-fHBP) vaccine for the prevention of meningococcal B disease. 2019; Lahra MM, et al. Commun Dis Intell. (2018). 2020.
In Asia Pacific, the burden of meningococcal disease is high among children and adolescents7
A second peak of meningococcal disease incidence occurs in adolescents and young adults.8
Adolescent behaviours lead to an increased carriage of N meningitidis.9
Adolescents and young adults are much more likely to be carriers of N meningitidis, having the highest carriage rate of all age groups.11
Adapted from Christensen H et al, 2010.
The incidence of meningococcal disease is approximately 1.5- to 3-fold higher in older adolescents/ young adults than in the general population based on the most recent surveillance data.13
EU, European Union; EEA, European Economic Area; IMD, Invasive meningococcal disease.
Immunocompromised individuals are more susceptible to meningococcal disease.2
Although several factors may contribute to the susceptibility of an individual to meningococcal disease, the ability to mount a serum bactericidal response is probably the most important.2
Individuals are at increased risk (from 2- to 20-fold) when they have conditions such as3:
Approval Code: BF0098OA686/052023
Invalidation date: 10/05/2025
Adverse events should be reported. Adverse events can be reported to [email protected]
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
The product information provided in this site is intended only for Healthcare Professionals of Egypt. The products discussed herein may have different product labeling in different countries.
Copyright © 2023 Pfizer biopharmaceutical LLC. All rights reserved.
These pages are not intended for patients or members of the general public. This portal contains healthcare promotional content.
If you select ‘No’, you will be redirected to Pfizer.com, the global Pfizer website.
I confirm that I am a healthcare professional resident in Egypt.